Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Well known in his field as an authority on the design, development and testing of vaccines for adults and children, over the past eighteen months, his capacity as Director of the Oxford Vaccine Group has catapulted him to wider recognition as a public figure in the fight against COVID-19. The development of the Oxford-AstraZeneca vaccine has had an immeasurable impact on the lives of children and young people across the world. His wider work has also had a profound impact on childhood immunisation in the UK, supporting the introduction of half of the vaccines currently given to children.

Andrew obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001.

Read the full story on the Department of Paediatrics website. 

Similar stories

Increased risk of some neurological and psychiatric disorders remains two years after COVID-19 infection

New diagnoses of disorders including psychosis, dementia, seizures and ‘brain fog’ remain commoner two years after COVID-19 than after other respiratory infections, whereas the increased risks of depression and anxiety after COVID-19 are short-lived and there is no overall excess of cases.

Sensory Supermarket event helps businesses make public-facing spaces more inclusive for autistic people

Researchers from the Universities of Oxford and Reading – in collaboration with awareness-raising organisation Sensory Spectacle – are hosting an innovative event called Sensory Supermarket as part of the Sensory Street research project.

Genetic mapping of tumours reveals how cancers grow

Researchers from the University of Oxford, KTH Royal Institute of Technology, Science for Life Laboratory, and the Karolinska Institutet, Solna, Sweden, have found that individual prostate tumours contain a previously unknown range of genetic variation.

Tackling suicide risk in people with mental disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Environmental impact of 57,000 multi-ingredient processed foods revealed

A study estimating the environmental impact of 57,000 food products in the UK and Ireland has been published by an Oxford-led research team in the journal PNAS.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.